Th1 response and systemic treg deficiency in inclusion body myositis

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Allenbach, Yves ^a,b   Chaara, Wahiba ^a,b   Rosenzwajg, Michelle ^a,b   Six, Adrien ^a,b   Prevel, Nicolas ^a   Mingozzi, Federico ^c,d,e   Wanschitz, Julia ^f   Musset, Lucile ^c   Charuel, Jean Luc ^c   Eymard, Bruno ^c   Salomon, Benoit ^a   Duyckaerts, Charles ^c   Maisonobe, Thierry ^c   Dubourg, Odile ^c   Herson, Serge ^b   Klatzmann, David ^a,b   Benveniste, Olivier ^b,c,d  

^a Unit of Dermatology   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d INSERM   (France)

^e GÉNÉTHON   (France)

^f INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CXCL9 CHEMOKINE; EOTAXIN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 7 RECEPTOR; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; CD28 ANTIGEN; CHEMOKINE;

AGED; ARTICLE; CD28- T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL LINEAGE; CELLULAR IMMUNITY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOXP3 GENE; GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; INCLUSION BODY MYOSITIS; LYMPHOCYTE DIFFERENTIATION; MALE; MUSCLE TISSUE; PHENOTYPE; POLARIZATION; REGULATORY T LYMPHOCYTE; SPORADIC INCLUSION BODY MYOSITIS; T CELL DEPLETION; TH1 CELL; TISSUE LEVEL; BIOSYNTHESIS; BLOOD; CASE CONTROL STUDY; CELL POLARITY; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LYMPHOCYTE COUNT; METABOLISM; PATHOLOGY;

AGED; ANTIGENS, CD28; CASE-CONTROL STUDIES; CELL LINEAGE; CELL POLARITY; CHEMOKINES; FEMALE; HUMANS; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; LYMPHOCYTE COUNT; MALE; MYOSITIS, INCLUSION BODY; PHENOTYPE; T-LYMPHOCYTES, REGULATORY; TH1 CELLS;

EID: 84897067178     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088788     Document Type: Article

References (31)

1. Benveniste O, Guiguet M, Freebody J, Dubourg O, Squier W, et al. (2011) Long-term observational study of sporadic body inclusion body myositis. Brain 134(Pt11): 3176-84.
2. Dimitri D, Benveniste O, Dubourg O, Maisonobe T, Eymard B, et al. (2006) Shared blood and muscle CD8+ T-cell expansions in inclusion body myositis. Brain, 129(Pt 4): 986-995.
3. Askanas V, Engel WK (2008) Inclusion-body myositis: muscle-fiber molecular pathology and possible pathogenic significance of its similarity to Alzheimer's and Parkinson's disease brains. Acta Neuropathol, 116(6): 583-595.
4. Greenberg SA (2010) Comment on alemtuzumab and inclusion body myositis. Brain, 133(Pt 5): e135; author reply e136.
5. Griggs RC, Askanas V, DiMauro S, Engel A, Karpati G, et al. (1995) Inclusion body myositis and myopathies. Ann Neurol 38(5): 705-713.
6. Dubourg O, Wanschitz J, Maisonobe T, Behin A, Allenbach Y, et al. (2011) Diagnostic value of markers of muscle degeneration in sporadic inclusion body myositis. Acta Myol, 30(2): 103-108.
7. Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, et al. (2004) 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord, 14(5): 337-345. (Pubitemid 38507409)
8. Guillot-Delost M, Cherai M, Hamel Y, Rosenzwajg M, Baillou C, et al. (2008) Clinical-grade preparation of human natural regulatory T-cells encoding the thymidine kinase suicide gene as a safety gene. J Gene Med, 10(8): 834-846.
9. Baird GS, Montine TJ (2008) Multiplex immunoassay analysis of cytokines in idiopathic inflammatory myopathy. Arch Pathol Lab Med, 132(2): 232-238. (Pubitemid 351213792)
10. Terrier B, Geri G, Chaara W, Allenbach Y, Rosenzwajg M, et al. (2012) Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis. Arthritis Rheum, 64(6): 2001-2011.
11. Effros RB, Dagarag M, Spaulding C, Man J (2005) The role of CD8+ T-cell replicative senescence in human aging. Immunol Rev, 205: 147-157. (Pubitemid 40780183)
12. Gregg R, Smith CM, Clark FJ, Dunnion D, Khan N, et al. (2005) The number of human peripheral blood CD4+ CD25high regulatory T cells increases with age. Clin Exp Immunol, 140(3): 540-546. (Pubitemid 40813966)
13. Appay V, van Lier RA, Sallusto F, Roederer M (2008) Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry A, 73(11):975-983.
14. Sakaguchi S, Yamaguchi T, Nomura T, Ono M (2008) Regulatory T cells and immune tolerance. Cell, 133(5): 775-787. (Pubitemid 351707693)
15. Wang J, Ioan-Facsinay A, van der Voort EI, Huizinga TW, Toes RE (2007) Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol, 37(1): 129-138. (Pubitemid 46128793)
16. Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, et al. (2009) Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity, 30(6): 899-911.
17. Lacotte S, Brun S, Muller S, Dumortier H (2009) CXCR3, inflammation, and autoimmune diseases. Ann N Y Acad Sci, 1173: 310-317.
18. Schmidt J, Barthel K, Wrede A, Salajegheh M, Bahr M, et al. (2008) Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. Brain, 131(Pt 5): 1228-1240.
19. De Paepe B, De Keyzer K, Martin JJ, De Bleecker JL (2005) Alpha-chemokine receptors CXCR1-3 and their ligands in idiopathic inflammatory myopathies. Acta Neuropathol, 109(6): 576-582. (Pubitemid 40974146)
20. Szodoray P, Alex P, Knowlton N, Centola M, Dozmorov I, et al. (2010) Idiopathic inflammatory myopathies, signified by distinctive peripheral cytokines, chemokines and the TNF family members B-cell activating factor and a proliferation inducing ligand. Rheumatology (Oxford, 49(10): 1867-1877.
21. Pandya JM, Fasth AE, Zong M, Arnardottir S, Dani L, et al. (2010) Expanded T cell receptor Vbeta-restricted T cells from patients with sporadic inclusion body myositis are proinflammatory and cytotoxic CD28null T cells. Arthritis Rheum, 62(11): 3457-3466.
22. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, et al. (2001) The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet, 27(1): 20-21. (Pubitemid 32044513)
23. Tang Q, Bluestone JA (2008) The Foxp3 + regulatory T cell: a jack of all trades, master of regulation. Nat Immunol, 9(3): 239-244. (Pubitemid 351267321)
24. Banica L, Besliu A, Pistol G, Stavaru C, Ionescu R, et al. (2009) Quantification and molecular characterization of regulatory T cells in connective tissue diseases. Autoimmunity, 42(1): 41-49.
25. Antiga E, Kretz CC, Klembt R, Massi D, Ruland V, et al. (2010) Characterization of regulatory T cells in patients with dermatomyositis. J Autoimmun, 35(4): 342-350.
26. Chi LJ, Wang HB, Zhang Y, Wang WZ (2007) Abnormality of circulating CD4(+)CD25(+) regulatory T cell in patients with Guillain-Barre syndrome. J Neuroimmunol, 192(1-2): 206-214. (Pubitemid 350213129)
27. Zhang B, Zhang X, Tang F, Zhu L, Liu Y (2008) Reduction of forkhead box P3 levels in CD4+CD25high T cells in patients with new-onset systemic lupus erythematosus. Clin Exp Immunol, 153(2): 182-187. (Pubitemid 351989160)
28. Li X, Xiao BG, Xi JY, Lu CZ, Lu JH (2008) Decrease of CD4(+)CD25(high)Foxp3(+) regulatory T cells and elevation of CD19(+)BAFF-R(+) B cells and soluble ICAM-1 in myasthenia gravis. Clin Immunol, 126(2): 180-188.
29. Chen W, Jin W, Hardegen N, Lei KJ, Li L, et al. (2003) Conversion of peripheral CD4 +CD252 naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med, 198(12): 1875-1886. (Pubitemid 38032120)
30. Taflin C, Miyara M, Nochy D, Valeyre D, Naccache JM, et al. (2009) FoxP3+ regulatory T cells suppress early stages of granuloma formation but have little impact on sarcoidosis lesions. Am J Pathol, 174(2): 497-508.
31. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA (2004) Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med, 199(7): 971-979. (Pubitemid 38481088)